Cardiovascular Diseases

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like ischemic stroke and acute myocardial infarction or heart attack. The clinical trial was the first-in-man placebo-controlled study that aimed to demonstrate safety and tolerability of the interventional drug in healthy adults. Brainstorm starts the Phase III trial investigating NurOwn for ALS in the US BrainStorm Cell Therapeutics have announced the initiatio...